Recently, the first oral form of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide (Rybelsus®) has been launched as a treatment for type 2 diabetes [1] and shown to potently ameliorate obesity as well as diabetes [2]. Here, GLP1R is linked to type 2 diabetes mellitus.